SNDX News and Press, Syndax Pharmaceuticals Inc. From 05/09/22

Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update PR Newswire – Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA fi...

ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...

Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022 PR Newswire WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-...

Gainers: Super Micro Computer (SMCI) +14%. Luminar Technologies (LAZR) +5%. Veeco Instruments  (VECO) +5%. CytomX Therapeutics (CTMX) +5%. Syndax Pharmaceuticals (SNDX) +5%. Losers: NETGEAR (NTGR) -11%. Lakeland Industries (LAKE) -9%. ACADIA Pharmaceuticals ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Advanced Micro Devices (NASDAQ: AMD ): A former penny stock that turned insanely profitable, became a $100 stock in less than five years BBQ Holdings (NASDAQ: BBQ ): Stock rose from $1.65 per share lows to ne...

Today's $19 share quote is backed by as much as $7.50 in cash vs. total liabilities under $1 per unit. Larger drug trials are underway testing the usefulness of two cancer-related products. Strong technical momentum trends have been building since December. For further detai...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this event. For further details see: Syndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare Conference

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass. , March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical compa...

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael Metzger - Chief Executive Officer Alexander Nolte - Chief Accounting Officer Anjali Ganguli - Chief Business Officer Briggs...

The clinical-stage biotech, Syndax Pharmaceuticals (NASDAQ:SNDX), announced on Tuesday that Kate Madigan, M.D., will be appointed as the company’s new Chief Medical Officer, effective immediately. She will replace Michael Meyers, who will remain with the company until June before takin...